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A B S T R A C T
Background
Emergency contraception can prevent pregnancy when taken after unprotected intercourse. Obtaining emergency contraception within
the recommended time frame is difficult for many women. Advance provision could circumvent some obstacles to timely use.
Objectives
To summarize randomized controlled trials evaluating advance provision of emergency contraception to explore effects on pregnancy
rates, sexually transmitted infections, and sexual and contraceptive behaviors.
Search strategy
In November 2009, we searched CENTRAL, EMBASE, POPLINE, MEDLINE via PubMed, and a specialized emergency contracep-
tion article database. We also searched reference lists and contacted experts to identify additional published or unpublished trials.
Selection criteria
We included randomized controlled trials comparing advance provision and standard access (i.e., counseling whichmay ormay not have
included information about emergency contraception, or provision of emergency contraception on request at a clinic or pharmacy).
Data collection and analysis
Two reviewers independently abstracted data and assessed study quality. We entered and analyzed data using RevMan 5.0.23.
Main results
Eleven randomized controlled trials met our criteria for inclusion, representing 7695 patients in the United States, China, India and
Sweden. Advance provision did not decrease pregnancy rates (odds ratio (OR) 0.98, 95% confidence interval (CI) 0.76 to 1.25 in
studies for which we included twelve-month follow-up data; OR 0.48, 95% CI 0.18 to 1.29 in a study with seven-month follow-up
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data; OR 0.92, 95% CI 0.70 to 1.20 in studies for which we included six-month follow-up data; OR 0.49, 95% CI 0.09 to 2.74 in a
study with three-month follow-up data), despite reported increased use (single use: OR 2.47, 95% CI 1.80 to 3.40; multiple use: OR
4.13, 95% CI 1.77 to 9.63) and faster use (weighted mean difference (WMD) -12.98 hours, 95% CI -16.66 to -9.31 hours). Advance
provision did not lead to increased rates of sexually transmitted infections (OR 1.01, 95% CI 0.75 to 1.37), increased frequency of
unprotected intercourse, or changes in contraceptive methods. Women who received emergency contraception in advance were equally
likely to use condoms as other women.
Authors’ conclusions
Advance provision of emergency contraception did not reduce pregnancy rates when compared to conventional provision. Results from
primary analyses suggest that advance provision does not negatively impact sexual and reproductive health behaviors and outcomes.
Women should have easy access to emergency contraception, because it can decrease the chance of pregnancy.However, the interventions
tested thus far have not reduced overall pregnancy rates in the populations studied.
P L A I N L A N G U A G E S U M M A R Y
Easier access to emergency contraception to help women prevent unwanted pregnancy
Emergency contraceptive pills can prevent unwanted pregnancy if taken soon after unprotected sex. Getting a prescription for emergency
contraception can be difficult and time-consuming. Giving emergency contraception to women in advance could ensure that women
have it on hand in case they need it. We searched for studies comparing women who got emergency contraception in advance to women
who got it in standard ways. We examined whether these groups had different rates of pregnancy or sexually transmitted infections. We
also studied how often and how quickly both groups used emergency contraception. Finally, we looked at whether advance provision
of emergency contraception changed sexual behavior. Studies showed that the chance of pregnancy was similar regardless of whether
or not women have emergency contraception on hand before unprotected sex. Women who had emergency contraception in advance
were more likely to report use of the medication, and to use it sooner after sex. Having emergency contraception on hand did not
change use of other kinds of contraception or change sexual behavior.
B A C K G R O U N D
Emergency contraception can prevent pregnancy when taken
within 120 hours of unprotected intercourse. Several types of
emergency contraception regimens exist, including an estrogen-
progestin combination (sometimes called “combined regimen” or
“Yuzpe regimen”), levonorgestrel alone, and mifepristone. An al-
ternate method of emergency contraception is post-coital inser-
tion of a copper-bearing intrauterine device (IUD), but this review
does not cover IUDs as emergency contraceptives.
Effectiveness and side effects vary by regimen (Cheng 2008). A
meta-analysis of eight studies suggested that combined regimens
reduce the risk of pregnancy by about 74% when taken within 72
hours of unprotected intercourse (Trussell 1999). A more recent
analysis using potentially improved methodology suggested lower
effectiveness rates, with the two largest studies showing rates of
47% and 53% (Trussell 2003). Levonorgestrel regimens are more
effective than combined regimens (with estimates ranging from
59-94%), with less nausea and vomiting (Task Force 1998; Trussell
2006a).
Several barriers discourage widespread and timely use of emer-
gency contraception, including limited knowledge among women
and a lack of routine counseling by providers and/or willingness
to prescribe the medication. In some countries, emergency con-
traception is available only after obtaining a prescription, which
can be difficult and time-consuming, particularly on holidays or
weekends when most clinics and physicians’ offices are closed.
Moreover, some women find it difficult or embarrassing to request
emergency contraception from their physician, and others may
not have a primary health care provider. Emergency contraception
should be taken as soon as possible, and most guidelines suggest
taking the medication within 72 or 120 hours of unprotected in-
tercourse. Even under ideal circumstances, obtaining a prescrip-
tion within 72 hours can be difficult (Trussell 2000); to date, no
studies have investigated barriers to accessing a prescription within
the 120 hour time limit. Some countries sell emergency contra-
ception over-the-counter without a prescription, and others allow
women to obtain emergency contraception directly from a phar-
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macist without a doctor’s prescription under collaborative practice
agreements with physicians or state approved protocols.
Providing emergency contraception before it is needed in case un-
protected intercourse occurs gives women rapid access to themed-
ication. This strategy was first evaluated in a 1998 study (Glasier
1998) and has received increased attention since that time. Eco-
nomic modeling indicates that advance provision of emergency
contraception is a cost-effective public health strategy (Trussell
2006a). However, some worry that having emergency contracep-
tion on hand may encourage repeat or incorrect use, increase risky
sexual behavior, or discourage use of ongoing or more reliable
methods of contraception (particularly barrier methods), thereby
increasing the risk of pregnancy or sexually transmitted infections
(Gold 1997; Golden 2001; Sherman 2001).
O B J E C T I V E S
To summarize randomized controlled trials evaluating advance
provision of emergency contraceptive pills.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review included all randomized controlled trials in English
that evaluated advance provision of emergency contraception. We
excluded studies that failed to clearly report the proportion of
women in each treatment arm who became pregnant (as deter-
mined by self-report and/or medical testing) during follow-up,
and for which we were unable to obtain clear data by asking au-
thors directly.
Types of participants
Women of reproductive age.
Types of interventions
Any emergency contraceptive regimen (combined, levonorgestrel,
or mifepristone) provided in advance of need compared to a con-
trol group, defined as any of the following: counseling which may
or may not include a discussion of emergency contraception, or
provision of emergency contraception on request at a clinic or
pharmacy.
Types of outcome measures
Primary outcome measures were pregnancy and sexually transmit-
ted infection rates. Secondary outcomes were frequency of emer-
gency contraception use, unprotected intercourse, use of more
effective methods of contraception, condom use, delay in tak-
ing emergency contraception after unprotected intercourse, and
knowledge about emergency contraception.
Search methods for identification of studies
See Helmerhorst 2001 for methods used in reviews of the Fertility
Regulation Group.
During August 2006, we identified relevant trials from the
Cochrane Central Register of Controlled Trials (CENTRAL)
on the Cochrane Library, EMBASE, POPLINE, MEDLINE
via PubMed, and the website of the International Consortium
for Emergency Contraception (www.cecinfo.org/database/who/
index.php). Where possible, searches were restricted to human
studies only. We restricted our search to English (Moher 2000;
Juni 2002). We updated our literature search in November 2009.
We used the following strategy to search CENTRAL:
((postcoital or emergency) and contracept* and (advance* or self
administr*))
We used the following strategy to search EMBASE:
(((’emergency’/exp OR ’emergency’) OR (’emergency’/exp OR
’emergency’)) OR postcoit*) AND (contracept*) AND (advance
AND provision OR advanced AND provision) AND [english]/
lim AND [humans]/lim
We used the following strategy to search POPLINE:
(emergency contraception/contraceptive agents, postcoital/fertil-
ity control, postcoital) & (advance provision/advanced provision/
self administration)
We used the following strategy to searchMEDLINE via PubMed:
(emergency contracepti* OR contraception, postcoital OR con-
traceptives, postcoital) AND (advance OR advanced OR self ad-
minist* OR home)
We used the following strategy to search the database of scientific
articles on the website of the International Consortium for Emer-
gency Contraception (ICEC) (http://www.cecinfo.org/database/
who/index.php):
“advance” or “advanced”
We also searched reference lists of included studies for informa-
tion about additional trials and contacted experts in the field for
information on additional published or unpublished trials.
Data collection and analysis
All studies that met our inclusion criteria were independently eval-
uated by two reviewers. We assessed the methodological quality
3Advance provision of emergency contraception for pregnancy prevention (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of each study using the guidelines described in the Cochrane Re-
viewers’ Handbook (Alderson 2004). We designed a data abstrac-
tion form, and the two reviewers abstracted the data separately.
Discrepancies about the inclusion of studies or about abstracted
data were resolved by discussion. When necessary, we contacted
researchers to obtain additional information about study methods
or outcome measures. We entered and analyzed the data using
Review Manager 5.
We calculated odds ratios (OR) with 95% confidence intervals
for dichotomous variables and weighted mean averages (WMA)
for continuous variables for which means and standard deviations
were reported.We tested the outcome data for heterogeneity using
the I2 statistic, and in cases where I2 exceeded 50%, we employed
a DerSimonian and Laird random-effects model to provide a more
conservative estimate of significance (DerSimonian 1986;Higgins
2003). Finally, we conducted sensitivity analyses based on rates of
loss to follow-up (Schulz 2006), in which studies that had rates of
loss to follow-up over 20% were excluded.
One study (Belzer 2005) collected 12-month follow-up informa-
tion, but due to the presentation of results, we were only able to
include 6-month follow-up information. In cases where data were
available, we calculated statistics using an intent-to-treat analysis
if the author failed to do so (Belzer 2005, see also Trussell 2006b).
To explore whether intervention effect waned over time, we con-
tacted authors of studies with 12 months of follow-up to obtain
pregnancy outcomes at six months, and pooled these outcomes
with studies which had a total follow-up time of six months. Six-
month pregnancy outcomes for Schreiber 2009 were not avail-
able. To explore whether pregnancy outcomes differed according
to type of regimen, we performed subgroup analyses of studies
using levonorgestrel, Yuzpe regimen, levonorgestrel or Yuzpe, and
mifepristone.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Eleven randomized controlled trials (Hazari 2000; Jackson 2003;
Gold 2004; Lo 2004; Belzer 2005; Hu 2005; Raine 2005;
Raymond 2006; Ekstrand 2008; Schwartz 2008; Schreiber 2009)
met our inclusion criteria. The total number of randomized par-
ticipants was 7695, with sample sizes ranging from 50 to 2000.
Raine 2005 enrolled 2117 total participants, but this review used
only two treatment groups of that study. Seven studies were con-
ducted in the United States (Jackson 2003; Gold 2004; Belzer
2005; Raine 2005; Raymond 2006; Schwartz 2008; Schreiber
2009), with five in California and the rest in Nevada, North Car-
olina, or Pennsylvania. One study was conducted in Hong Kong
(Lo 2004) and one in mainland China (Hu 2005). One study was
conducted in India (Hazari 2000) and one was conducted in Swe-
den (Ekstrand 2008). Six studies (Gold 2004; Belzer 2005; Raine
2005; Raymond 2006; Ekstrand 2008; Schreiber 2009) focused
specifically on younger populations, and twoof those (Belzer 2005;
Schreiber 2009) focused on adolescent mothers. Two studies pri-
marily enrolled post-partum women (Jackson 2003; Hu 2005).
Three studies recruited women from family planning clinics (Lo
2004; Raine 2005; Raymond 2006), two recruited from other
clinics (Ekstrand 2008; Schwartz 2008), four recruited from hos-
pitals (Jackson 2003; Gold 2004; Hu 2005; Schreiber 2009), and
one recruited adolescent mothers receiving case management ser-
vices (Belzer 2005). The recruitment site was unclear in one study
(Hazari 2000).
Exclusion criteria for baseline contraceptive use varied greatly be-
tween the studies. Themost restrictive criteria excludedwomenus-
ing or planning to use any hormonal method or an IUD (Lo 2004;
Hu 2005). Raymond 2006 excluded women for using some hor-
monal methods or sterilization, and Raine 2005 excluded women
for using some hormonal methods. Schwartz 2008 excluded IUD
users, women who had tubal sterilization or had partners who had
undergone a vasectomy, lesbians, and women who had a hysterec-
tomy. Gold 2004 excluded women using long acting contracep-
tive methods (IUD, implants and injectables), and Belzer 2005
excluded only IUD and implant users. Jackson 2003 excluded
women who were sterilized or had a sterilized partner. Three stud-
ies had minimal exclusion criteria: Hazari 2000 excluded only
women who were determined at baseline to be pregnant, Schreiber
2009 excluded women who desired a pregnancy in the next year,
and Ekstrand 2008 did not specify exclusion criteria based on
contraceptive use. Although several studies included post-partum
women, only one study specified excluding women who were cur-
rently breastfeeding (Raymond 2006).
Control groups also differed considerably. Three studies did not
necessarily provide any information about emergency contracep-
tion to the control group (Jackson 2003; Schwartz 2008; Schreiber
2009) Two studies (Belzer 2005; Hu 2005) specifically provided
information about emergency contraception to the control group,
but did not facilitate access to the medication in any other way.
Control participants in six studies (Hazari 2000; Gold 2004; Lo
2004; Raine 2005; Raymond 2006; Schreiber 2009) were able
to obtain emergency contraception on request at the clinic, al-
though not necessarily through study staff. One study provided the
control group with a dose of emergency contraception (Ekstrand
2008). Two studies reported providing all participants with con-
doms (Hazari 2000; Hu 2005), while Ekstrand 2008 provided
condoms only to the intervention group.
The number of courses of emergency contraception provided in
advance ranged from one to three. Seven studies provided only
one course of emergency contraception in advance (Hazari 2000;
Jackson 2003; Gold 2004; Belzer 2005; Ekstrand 2008; Schwartz
2008; Schreiber 2009). Gold 2004 offered two additional courses
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on request at the study office, Belzer 2005 and Schreiber 2009
offered replacement packs through the study, and Jackson 2003
provided instructions on obtaining additional emergency contra-
ceptive pills (but did not specify if that was through the study
office or by prescription). One study (Raymond 2006) provided
two courses in advance and made particular effort to ensure that
all women in the advance provision group had two courses avail-
able at all times. Finally, three studies provided three courses of
emergency contraception in advance (Lo 2004; Hu 2005; Raine
2005), and one (Lo 2004) specifically noted that women using all
three packs were instructed to return for contraceptive counseling
and, if appropriate, given three additional packets.
Most trials administered levonorgestrel pills. Seven studies used the
same formulation of pills (two tablets of 0.75 mg levonorgestrel)
(Lo 2004; Belzer 2005; Raine 2005; Raymond 2006; Ekstrand
2008; Schwartz 2008; Schreiber 2009). In addition, Gold 2004
replaced a Yuzpe regimen (200 µg ethinyl estradiol and 2 mg
norgestrel) with levonorgestrel when it became the standard of care
mid-way through their study. Two earlier studies used a combined
regimen (Hazari 2000; Jackson 2003), and one study based in
China provided 10 mg mifepristone (Hu 2005).
Follow-up ranged from three to 12 months. Six studies aimed
to follow all participants for one year (Jackson 2003; Lo 2004;
Belzer 2005; Hu 2005; Raymond 2006; Schreiber 2009). How-
ever, we report only on six-month follow-up data for most out-
comes (except pregnancy) in Jackson 2003 and all outcomes in
Belzer 2005, since these studies provided six-month data and six-
to 12-month data, but not cumulative 12-month data. Three stud-
ies followed all participants for six months (Gold 2004; Raine
2005; Ekstrand 2008), one study followed participants for seven
months (Schwartz 2008) and one study followed participants for
three months (Hazari 2000).
All studies attempted to measure pregnancy, whereas only four
studies measured sexually transmitted infections (Gold 2004;
Raine 2005; Raymond 2006;Ekstrand 2008). Seven studies solely
relied on self-reported pregnancy data (Jackson 2003; Gold 2004;
Belzer 2005; Hu 2005; Ekstrand 2008; Schwartz 2008; Schreiber
2009), whereas four studies used more objective pregnancy detec-
tion methods, comprised of some combination of self-report, test-
ing at follow-up, or medical chart review (Hazari 2000; Lo 2004;
Raine 2005; Raymond 2006). Among the studies whichmeasured
sexually transmitted infections, two used self-reported data (Gold
2004; Ekstrand 2008) and two used combinations of more ob-
jective methods including testing at follow-up and medical chart
review (Raine 2005; Raymond 2006).
Risk of bias in included studies
Eight studies used computer-generated randomization sequences
(Hazari 2000; Lo 2004; Belzer 2005; Hu 2005; Raine 2005;
Raymond 2006; Schwartz 2008; Schreiber 2009). One study ran-
domized in blocks of four using a table of random digits (Ekstrand
2008). One study had participants select a colored condom from a
covered bucket to determine allocation (Gold 2004), and another
used cluster randomization by date of discharge in order to avoid
accidental crossover (Jackson 2003).
Seven studies had adequate allocation concealment methods.
Four used either sequentially numbered, opaque, sealed envelopes
or identical treatment boxes (Lo 2004; Hu 2005; Raine 2005;
Raymond 2006) while three (Gold 2004; Hazari 2000; Schwartz
2008) used schemes undecipherable to clinic staff. Three studies
had unclear allocation concealment (Belzer 2005; Ekstrand 2008;
Schreiber 2009). One study had inadequate concealment methods
that allowed for assignment prediction (Jackson 2003).
Three studies (Hu 2005; Raine 2005; Raymond 2006) provided
sample size calculations based on detecting a decrease in pregnancy
rates. However, Hu 2005 was underpowered due to unexpectedly
low pregnancy rates in their study population. The other eight
studies primarily investigated behavior change and were not pow-
ered to measure pregnancy. Of these, four (Jackson 2003; Gold
2004; Lo 2004; Ekstrand 2008; Schwartz 2008) calculated sam-
ple sizes in accordance with anticipated differences in emergency
contraceptive use or timing of use between groups, two (Hazari
2000; Belzer 2005) did not provide sample-size calculations, and
one feasibility trial used a sample size of convenience (Schreiber
2009).
Five studies had loss to follow-up under 20% (Hazari 2000; Lo
2004; Hu 2005; Raine 2005; Raymond 2006). Six studies had
larger losses (Jackson 2003; Gold 2004; Belzer 2005; Ekstrand
2008; Schwartz 2008; Schreiber 2009), ranging up to 41% of
participants lost to follow-up (Schwartz 2008). In addition, Gold
2004 showed differential loss to follow-up.
Effects of interventions
None of the studies found significant differences in pregnancy rates
(Hazari 2000; Jackson 2003; Gold 2004; Lo 2004; Belzer 2005;
Hu 2005; Raine 2005; Raymond 2006; Ekstrand 2008; Schwartz
2008; Schreiber 2009), including the two studies that were ad-
equately powered to detect a difference (Raine 2005; Raymond
2006). Furthermore, results from the pooled analyses showed no
significant difference in pregnancy rates between advance provi-
sion and control groups. The combined OR for pregnancy com-
paring women receiving emergency contraception in advance to
women in the control group was 0.98 (95% CI 0.76 to 1.25) in
studies with 12-month follow-up, 0.48 (95% CI 0.18 to 1.29) in
a study with seven-month follow-up information, 0.92 (95% CI
0.70 to 1.20) in studies for which we included six-month follow-
up information, and 0.49 (95% CI: 0.09 to 2.74) for one study
with three-month follow-up data. Restricting this comparison in a
sensitivity analysis to include only studies with a loss to follow-up
rate under 20% did not substantially change the results (twelve-
month follow-up: OR 1.0; 95% CI 0.76 to 1.31; six-month fol-
low-up: OR 1.00; 95% CI 0.73 to 1.37; three-month follow-up:
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OR 0.49; 95% CI 0.09 to 2.74). None of the analyses pooled by
regimen type demonstrated a reduction in pregnancy rates (lev-
onorgestrel only: OR 0.82, 95%CI: 0.64 to 1.05; Yuzpe only: OR
0.90, 95% CI: 0.47 to 1.74; levonorgestrel or Yuzpe: OR 0.83,
95% CI: 0.67 to 1.03; and mifepristone: OR 1.20, 95% CI: 0.74
to 1.93).
None of the four studies that measured sexually transmitted in-
fection rates found significant differences between groups (Gold
2004; Raine 2005; Raymond 2006; Ekstrand 2008). The com-
bined OR for sexually transmitted infections was 1.01 (95% CI
0.75 to 1.37). Restricting this analysis to only studies with a loss to
follow-up rate under 20% did not substantially change the results
(OR 0.96; 95% CI 0.69 to 1.33).
Reported emergency contraceptive use was significantly higher in
the advance provision group in six studies (Jackson 2003; Lo 2004;
Hu 2005; Raine 2005; Raymond 2006; Ekstrand 2008), and in
four studies (Hazari 2000;Gold 2004; Schwartz 2008; Schreiber
2009), emergency contraceptive use was higher but the difference
did not reach statistical significance. Belzer 2005 reported emer-
gency contraceptive use only for a subgroup of participants and we
did not include those results in this analysis. The combined OR
for emergency contraception use for all studies was 2.47 (95% CI
1.80 to 3.40). The sensitivity analysis including only studies with a
loss to follow-up rate under 20% yielded similar results (OR 2.55;
95% CI 1.64 to 3.97). A secondary analysis which used predictive
modeling to estimate the baseline risk of pregnancy suggested that
women at lowbaseline risk of pregnancymay have beenmore likely
to use EC repeatedly than high risk women (Baecher 2009). Three
studies (Hu 2005; Raine 2005; Raymond 2006) also showed that
women in the advance provision group were significantly more
likely to use emergency contraception two or more times (OR:
4.13; 95% CI 1.77 to 9.63); no sensitivity analysis was conducted
for this outcome since all studies in the original analysis had loss
to follow-up under 20%.
The percentage of women who did not use emergency contracep-
tion after unprotected intercourse ranged widely and was reported
in different ways. Four studies (Jackson 2003; Lo 2004; Hu 2005;
Raymond 2006) reported non-use of emergency contraception
amongwomenwho became pregnant. Three studies reported non-
use among women who had unprotected intercourse (Gold 2004;
Raine 2005; Ekstrand 2008). In all studies reporting on non-use,
non-use was lower among participants in the advance provision
group compared to controls. Belzer 2005 reported use of emer-
gency contraception among a subgroup of participants (data not
reported).
Hu 2005 reported non-use of emergency contraception among
women who became pregnant during one year of follow-up (n=
70); 79% in the advance provision group and 100% in the control
group did not use emergency contraception during the cycle in
which they conceived. Among women who became pregnant in
Jackson 2003 (n=27), 64% in the advance provision group and
100% in the control group did not use emergency contraception.
Among women who became pregnant in Lo 2004 (n=16), 71%
in the advance provision group and 100% in the control group
did not report using emergency contraception during the cycle in
which the pregnancy occurred. Raymond 2006 reported that for
the 148 menstrual cycles in which women experienced pregnancy,
77%ofwomen in the advance provision group and 97%ofwomen
in the control group did not use emergency contraception during
those cycles.
Gold 2004 reported that at six-month follow-up, 26% of partici-
pants in both arms had unprotected intercourse in the past month,
but 92% of women in the advance provision group and 94% in the
control group did not report use of emergency contraception. In
Raine 2005, amongwomenwho reported ever having unprotected
sex, 6% of women in the advance provision group and 49% of
women in the control group did not report using emergency con-
traception during the study period. Ekstrand 2008 reported that
half of adolescent girls reporting unprotected intercourse during
the previous six months used ECP afterwards, with significantly
more in intervention group using emergency contraceptive pills
(58%) than in the control group (37%) (p=0.02).
In addition, emergency contraception was sometimes used incor-
rectly. Lo 2004 reported that although all participants took the
first dose within 72 hours of intercourse, 17% of women in the
advance provision group took the second dose of levonorgestrel
incorrectly. No women in the control group reported taking the
second dose incorrectly. Jackson 2003 reported incorrect use only
among women who became pregnant and who reported using
emergency contraception in the cycle in which they conceived (n=
4). Two of these four women used emergency contraception incor-
rectly. Hu 2005 reported that all women in the advance provision
group took emergency contraception within the recommended
120 hours, but did not report on correct use by control partici-
pants. Eight studies (Hazari 2000; Gold 2004; Belzer 2005; Raine
2005; Raymond 2006; Ekstrand 2008; Schwartz 2008; Schreiber
2009) did not report on incorrect use.
Five studies collected information on reported time intervals be-
tween unprotected intercourse and use of emergency contracep-
tion. In general, this interval was shorter for women receiving
emergency contraception in advance. Two studies provided mean
time and standard deviation (Lo 2004; Ekstrand 2008). Women
with advance provision took emergency contraception a mean of
12.98 hours earlier than women with standard provision (WMD -
13.98, 95% CI -16.66 to -9.31 hours). Two other studies reached
similar conclusions, the first with a comparison of median times of
11.4 hours for advance provision vs. 21.8 hrs for control (p=0.005)
(Gold 2004), the second with imputed median midpoints of 12
hours for advance provision vs. 36 hours for control (p<0.010)
(Raymond 2006). Raine 2005 also found a shorter delay for the
advance provision group (p=0.008). One study suggested no dif-
ference in timing (eight hours for both groups), but this study was
conducted in China, where levonorgestrel was available over-the-
counter at the time of the study (Hu 2005). A small number of
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women (n=2) in this study did report purchasing levonorgestrel
over the counter.
Eight studies compared the reported frequency of unprotected in-
tercourse using different time frames (Hazari 2000; Jackson 2003;
Gold 2004; Belzer 2005; Raine 2005; Raymond 2006; Ekstrand
2008; Schwartz 2008).None showed any difference between com-
parison groups (unprotected intercourse in past two weeks: OR
0.84 (95% CI 0.66 to 1.06); unprotected intercourse in past
month: OR 0.95 (95% CI 0.46 to 1.94); unprotected intercourse
in past three months: OR 1.28 (95% CI: 0.73 to 2.24); unpro-
tected intercourse in past six months: OR 0.96 (95% CI 0.79 to
1.16)).
Six studies examined change in contraceptive use using a variety of
measurements (Jackson 2003; Belzer 2005; Hu 2005; Raine 2005;
Raymond 2006; Ekstrand 2008). Belzer 2005 described this in-
formation only for a subgroup (data not reported). Jackson 2003
found no differences between treatment arms in consistency of
contraceptive use or type of method use during six months of fol-
low-up, and among women who only used condoms, there was no
decrease in condom use among the group with advance provision
of emergency contraception. Similarly, Hu 2005, Raine 2005 and
Ekstrand 2008 reported no differences between treatment arms in
patterns of contraceptive use ormethod change. Finally, Raymond
2006 reported that use of contraception (other than emergency
contraception) as reported at follow-up did not differ significantly
by group. In this study, the proportion of sexually active women
who did not use any form of contraception decreased slightly in
both groups during follow-up. Secondary analyses of this study
suggested that advance provision may have caused an increase in
unprotected or underprotected sex (Raymond 2008), and that ad-
vance provisionmay have causedwomen to substitute EC for other
methods (Weaver 2009), but these findings should be considered
hypothesis-generating and do not influence our overall conclu-
sions.
Eight studies looked at condom use; none found significant dif-
ferences between groups (Lo 2004; Belzer 2005; Hu 2005; Raine
2005; Raymond 2006; Gold 2004; Ekstrand 2008; Schwartz
2008). The OR for condom use at 12 months was 1.01 (95% CI
0.87 to 1.16); at six months: OR 0.94 (95% CI 0.66 to 1.34),
at three months: OR 0.77 (95% CI 0.48 to 1.25), in last month:
OR 1.54 (95% CI 0.94 to 2.53), and at last sex: OR 1.18 (95%
CI 0.71 to 1.94).
None of the studies reported adverse events (Hazari 2000; Jackson
2003; Gold 2004; Lo 2004; Belzer 2005; Hu 2005; Raine 2005;
Raymond 2006; Ekstrand 2008; Schwartz 2008; Schreiber 2009).
D I S C U S S I O N
Advance provision of emergency contraception did not reduce
unplanned pregnancies when compared to standard access. None
of the adequately powered trials found a decrease in pregnancy
rates with advance provision of emergency contraception (Raine
2005;Raymond 2006). Pooled estimates also showednodifference
in pregnancy rates, indicating that based on available data, advance
provision of emergency contraception does not lead to reduced
rates of unintended pregnancy. Analyses by length of follow-up
and by type of regimen did not change results.
This conclusion conflicts with earlier optimistic projections of the
potential public health impact of improved access (Trussell 1992).
Emergency contraception is more effective than placebo in pre-
venting unwanted pregnancy (Raymond 2004), and advance pro-
vision increases use and shortens time between unprotected in-
tercourse and emergency contraceptive use. Since evidence now
supports ia single dose of levonorgestrel 1.5 mg, and several coun-
tries now market levonorgestrel emergency contraception in a sin-
gle dose, incorrect use will likely be less of a problem in the fu-
ture (Arowojolu 2002; von Hertzen 2002). Nevertheless, women
may not perceive themselves to be at risk of pregnancy and may
fail to use the method after unprotected sex has occurred, de-
spite ready availability. Research suggests that unperceived preg-
nancy risk, concerns about side effects, and inconvenience are
some of the reasons why women may not use emergency contra-
ception when needed (Sorensen 2000;Moreau 2005; Rocca 2007;
Goulard 2006). A secondary analysis of data from Raymond 2006
suggested that women at the lowest baseline risk of pregnancy may
have been more likely to use EC repeatedly than high risk women,
which may help to explain why no effect on pregnancy was found
(Baecher 2009).
As with other contraceptive methods, the disparity between theo-
retical and actual effectiveness can be large (Steiner 1996). More
precise estimates of efficacy may help to shed light on advance
provision’s lack of impact on unintended pregnancy.
These trials share a common weakness. Reported information on
use of emergency contraception, frequency of unprotected inter-
course, and changes in contraceptive patterns was of unknown
validity. Since these self reports lacked objective verification, this
information should be viewed with caution (Stuart 2009). Objec-
tive evidence indicates that self reports on use of contraceptives
(Lawson 1998; Macaluso 2003; Walsh 2003; Galvao 2005) and
other medications (Landry 2006) are inaccurate, and that self-re-
port of unprotected intercourse is inferior to other ascertainment
methods (Rogers 2005). Some degree of underreporting of preg-
nancies may have occurred in both the advance provision and con-
trol groups in these trials, particularly those trials using only self-
reported data. Induced abortions are routinely underreported (Fu
1998). However, results from the trials relying on pregnancy test-
ing were consistent with results from the trials using self-reports
of pregnancy.
Advance provision of emergency contraception consistently in-
creased its reported use and usually shortened the reported interval
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between unprotected intercourse and drug administration. How-
ever, changes in these measures did not correlate with changes in
pregnancy rates.
The quality of these randomized controlled trials varied widely.
While many had good methods of randomization and allocation
concealment, follow-up rates differed greatly. One trial planned
not to followmost participants after randomization (Walsh 2006),
so we excluded it. In the view of Sackett and others, when losses
exceed 20% of participants randomized, the credibility of a trial is
suspect (Schulz 2006). Trials with high losses to follow-up resem-
ble cohort studies in their potential for bias. For the sake of com-
pleteness, we included trials with poor follow-up and performed a
sensitivity analysis with and without these reports; the results were
similar.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Providing women with emergency contraception in advance of
need does not reduce unintended pregnancy on a population level.
Advance provision did not have any harmful effects in primary
analyses: it did not increase rates of sexually transmitted infections,
decrease condom use, encourage adoption of less reliable contra-
ceptive methods, or otherwise negatively impact sexual and repro-
ductive behavior. While derivative studies suggested theoretical
concerns regarding increases in unprotected or underprotected sex,
or potential substitution of EC for more effective methods, these
findings should be considered tentative. Advance provision did
increase use of emergency contraception and decrease the length
of time between unprotected intercourse and use of emergency
contraception. Conclusions about population level effects should
not impede efforts to ensure all women have access to emergency
contraception when they need it. Women should be given infor-
mation about and easy access to emergency contraception because
individual women can decrease their chances of pregnancy by us-
ing the method. However, current data on advance provision of
emergency contraception indicate that tested interventions will
not reduce overall unintended pregnancy rates.
Implications for research
Future research should address the behavioral issues surrounding
the failure to use emergency contraception when needed, even
when it is readily available.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Belzer 2005
Methods RCT. Computer generated randomization number table. Sealed envelopes (unclear whether opaque or sequentially
numbered). 12 mo follow-up, data reported in six mo intervals. We utilize only the six mo data.
Participants 160 adolescent mothers, 13-20 yrs, mostly Hispanic, receiving case management services in a large metropolitan area.
Excluded if attempting to get pregnant or using implant or an IUD.
Interventions Intervention group received 1 course levonorgestrel-only regimen (two tabs 0.75 mg levonorgestrel), to be taken in
two doses 12 h apart. Replacement pack provided if package used or lost. Control group received EC info only.
Outcomes Pregnancy rates, frequency of unprotected intercourse, condom use.
Notes Large loss to follow-up (31% at six months). Original statistical analysis not intent-to-treat. All self-reported data.
No sample size calculation. Controls significantly more likely to report condom use and sexual activity at baseline;
differences not controlled for in analysis.
Ekstrand 2008
Methods RCT. Randomization in blocks of four using a table of random digits. Sequentially labeled envelopes (unclear whether
opaque or sealed). Six mo follow-up, data reported at three and six months.
Participants 420 Swedish teens, 15-19 yrs, requesting EC in a local youth clinic in medium-sized university town in Sweden.
Excluded if had a language barrier.
Interventions Intervention group received requested dose plus extra dose (1.5 mg levonorgestrel taken as a single dose), plus 10
condoms and a leaflet on EC and condom use. Control group received requested dose of EC.
Outcomes Pregnancy rates, STI rates (unspecified), use of EC, interval between unprotected sex and EC use, frequency of
unprotected sex, condom use
Notes All self-reported data. Large loss to follow-up (22% at six months). Not powered to detect differences in pregnancy
or STI rates.
Gold 2004
Methods RCT (by colored condom chosen from age-stratified bucket). Correspondence with primary author indi-
cated that participants could not see inside bucket before choosing and were unaware of the color assign-
ments. Two colors, distributed 50:50, inside each bucket. Most clinic staff unlikely to have been able to
decipher the color code, method unlikely to have affected randomization. Six mo follow-up.
Participants 301 sexually-active adolescents, aged 15-20 yrs, in Southwestern Pennsylvania, primarily minority and
low-income. Excluded if using IUD, implant, injectable, if living in foster care or group home, or if had
other characteristics which could threaten follow-up.
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Gold 2004 (Continued)
Interventions From study start until April 2000, intervention group received one course Yuzpe regimen 200 mcg ethinyl
estradiol plus 2mgnorgestrel, plus an extra dose in case of vomiting, in addition to diphenhydramine. After
April 2000, when levonorgestrel only regimens became standard of care, a levonorgestrel-only regimen was
used (two tabs of levonorgestrel 0.75 mg). Participants could obtain two additional courses over six mo
period by request, regardless of whether unprotected intercourse had occurred. Participants also received
counseling and EC info. Control group received EC on request at the clinic and EC info.
Outcomes Pregnancy and STI rates (specific STIs not specified), use of EC, interval between unprotected intercourse
and EC use, frequency of unprotected intercourse, condom use.
Notes Large loss to follow-up (26%at sixmo - for reasons other than pregnancy), and loss to follow-up differential
by treatment group (33% in advance provision group, 19% in control group). Not powered to detect
differences in pregnancy or STI rates.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Hazari 2000
Methods RCT. Coded randomization slips prepared off-site. Three mo follow-up.
Participants 200 condom-using women in Mumbai, India, generally low SES and mostly between the ages of 25-
34 yrs. Excluded if pregnant at baseline as determined by history of last menstrual period and recent
unprotected intercourse, vaginal exam, or if required, urine pregnancy test and ultrasonography.
Interventions Intervention group received one course Yuzpe regimen (50 µg ethinyl estradiol and 0.25mg levonorgestrel)
to be taken in two doses 12 h apart. Replacement pills were provided on request at the clinic. Control
group received EC on request at the clinic. Both groups were provided with condoms.
Outcomes Pregnancy rates, EC use, frequency of unprotected sex.
Notes Small loss to follow-up (1%). One pregnancy was missed at baseline, excluded from this review. Article
poorly described methodology, participants, and outcomes. Unclear whether differences between groups
at baseline. No discussion of sample size.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No
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Hu 2005
Methods RCT. Computer generated simple randomization list. Sequentially numbered, opaque, sealed envelopes.
12 mo follow-up.
Participants 2000 post-partum women in Shanghai hospital. Excluded if planning on using an IUD or hormonal
contraception.
Interventions Intervention group received three courses ofmifepristone (10mg). Control group received only informatin
on EC (but levonorgestrel available in China OTC). All participants received ten condoms.
Outcomes Pregnancy rates, use of EC, interval between unprotected intercourse and EC use, change in contraceptive
methods, condom use.
Notes Reasonable loss to follow-up (17%). Originally powered to detect a difference in pregnancy rates, but
pregnancy rates much lower than expected, reducing statistical power. Failure to perform intent-to-treat
analysis (inappropriately excluded those who chose IUD and sterilization). High potential for crossover
due to OTC levonorgestrel.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Jackson 2003
Methods RCT. Cluster randomization by date of discharge from postpartum care, done with random number
generator by separate researcher so clinic staff could not predict day’s assignment. Data analyzed by indi-
vidual, re-evaluated accounting for cluster sampling, no substantial differences. Researchers conducting
baseline interviews not masked to group assignment, blinded personnel conducted follow-up, data entry,
and analysis. 12 mo follow-up.
Participants 370 post-partum, low income, racially diverse English- or Spanish-speaking women at public inner-city
hospital in San Francisco. Excluded if major contraindications to estrogen use, post-partum tubal ligation
or partner with vasectomy, employees of Labor and Delivery at the hospital, enrolled in another study, or
difficult to reach for follow-up (lack of a phone, psychiatric disorder, untreated substance abuse, plans for
relocation).
Interventions Intervention group received one course of Yuzpe regimen (eight tabs 0.15 mg levonorgestrel plus 30
µg ethinyl estradiol), educational session, verbal and written instructions. Additional pills available on
request. Control group received routine counseling, which may or may not have included a discussion of
EC.
Outcomes Pregnancy rates, use of EC, frequency of unprotected intercourse, change in contraceptive methods, EC
knowledge. Except for pregnancy rates, most outcomes can only be included for six-month follow-up
data, as they were reported separately for the six months prior to the six and twelve-month follow-up
visits.
Notes Large loss to follow-up (31% at 12 months). All self-reported data. Powered to detect difference in EC
use.
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Jackson 2003 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No
Lo 2004
Methods RCT. Computer generated randomization list, blocks of 10. Sequentially numbered opaque, labeled,
sealed envelopes. 12 mo follow-up.
Participants 1030 women, 18-45 yrs, attending two Hong Kong clinics using “less effective contraceptive methods” (
condoms, spermicide, fertility awareness based methods, withdrawal, or nothing).
Interventions Intervention group received three courses (two tabs 0.75 mg levonorgestrel), to be taken in two doses 12
h apart, and up to three more courses if needed. Control group received EC on request at clinic.
Outcomes Pregnancy rates, use of EC, interval between unprotected intercourse and EC use, condom use.
Notes Small loss to follow-up (4%). Pregnancy confirmed by pregnancy test. Powered to detect a 10% difference
in EC use, not powered to detect a difference in pregnancy rates.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Raine 2005
Methods RCT. Computer generated randomization sequence assigned participants to one of three groups before
December 2001, to one of two groups after December 2001 (clinic access group eliminated because
pharmacy access instated in CA). We include only data from intervention and clinic access groups (pre
12/2001). Sequentially numbered treatment boxes with labeled study ID, opened after leaving the clinic.
Six mo follow-up.
Participants 1228 English or Spanish speaking women, 15-24 yrs, sexually active in past six mo, largely uninsured and
low-income, at moderately high risk for negative reproductive health outcomes, living in the San Francisco
Bay area, attending four California family planning clinics, available for six mo follow-up. Excluded if
pregnant or desiring pregnancy, using hormonal contraception or IUD, or if had unprotected intercourse
during the past three days or were requesting EC at enrollment.
Interventions Intervention group received three courses (two tabs 0.75 mg levonorgestrel), to be taken in two doses 12 h
apart, within 72 hours of intercourse. Control group received EC on demand at a clinic. Although EC is
generally available at no cost through the clinic, some study participants ineligible for insurance coverage
may have had to pay all or some of the cost of EC at two of the four study sites.
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Raine 2005 (Continued)
Outcomes Pregnancy rates, STI rates (only information on Chlamydia and HSV2 included because these STIs
were confirmed by testing at follow-up) use of EC, frequency of unprotected intercourse, change in
contraceptive methods, condom use.
Notes Small loss to follow-up (7% at six months). Some crossover reported. This review excludes information
from pharmacy access group as we are interested in comparing advance provision and standard access (
before statewide pharmacy access was implemented). Participants differed at baseline by enrollment site,
race/ethnicity was linked to enrollment site. Differences controlled for, adjustment did not substantially
change results. Powered to detect a difference in pregnancy rates.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Raymond 2006
Methods RCT. Computer generated randomization scheme in blocks of four, six, and eight. Sequentially numbered,
opaque, sealed envelopes. 12 mo follow-up.
Participants 1490 sexually active women, 14-24 yrs, who did not desire pregnancy and were attending clinics inNevada
and North Carolina. Excluded if using or planning on using sterilization, IUD, hormonal contraception,
or if pregnant or breastfeeding in past 6 wks.
Interventions Intervention group received two courses (two tabs of 0.75 mg levonorgestrel) to be taken together in one
dose. More courses provided, attempt to ensure two packages on hand at all times. Control group received
EC on request at a clinic.
Outcomes Pregnancy rates, STI rates (gonorrhea, Chlamydia, trichomoniasis), use of EC, interval between unpro-
tected intercourse and EC use, frequency of unprotected intercourse, change in contraceptive methods,
condom use.
Notes Small loss to follow-up (6%). Pregnancy and STIs outcomes based primarily on medical chart review plus
testing at follow-up, some women self-tested at home, sent vaginal samples for confirmation. Powered to
detect a difference in pregnancy rates. More intervention participants had STIs at baseline; differences
controlled for, adjustment did not substantially change results.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
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Schreiber 2009
Methods RCT. Randomization generated in permutated blocks in research unit by computer before recruitment phase. As-
signments placed in sealed envelopes in consecutive order. Not clear if envelopes were opaque. 12-month follow-up.
Participants 50 young (14-19 yrs), English-speaking women recruited from a hospital post-partum unit who had delivered a live
infant and were planning to parent, who desired to delay pregnancy for at least one year, and who were in good general
health. Excluded if had allergy to levonorgestrel, current substance abuse, or plans to relocate outside of Philadelphia.
Interventions Intervention group received one package of emergency contraceptive pills (Plan B) with routine instructions about
EC as well as the chosen primary contraceptive method, a prescription for chosen primary method when applicable,
or the first dose of injectable contraception (if injectable contraception was the chosen method). The intervention
group had access to additional packages of Plan B upon request. Control group participants were discharged with
instructions about their chosen primary contraceptive method and a prescription or first dose for that method.
Outcomes Pregnancy rates, EC use.
Notes Large loss to follow-up (24% at 12 months). All outcomes self-reported.
Schwartz 2008
Methods RCT. Computerized randomization with automatic launching of counseling modules after baseline ques-
tionnaire (Research assistant remained unaware of allocation until counseling was completed). follow-up
phone survey by blinded participants. Seven mo follow-up.
Participants 446 English-speaking adult women (18-45 yrs) from waiting areas of two urgent care clinics in San
Francisco who had a phone and no plans to relocate. Excluded if pregnant, had a hysterectomy or tubal
ligation, had an IUD, had a partner with vasectomy, or a lesbian.
Interventions Intervention group received a single package of two 0.75 mg levonorgestrel pills and computerized con-
seling on EC. Control group received computerized counseling about pre-conception folate and a sample
of folate.
Outcomes Pregnancy rates, use of EC, unprotected sex in last six months, condom use.
Notes Large loss to follow-up (41% at seven months). All outcomes self-reported. Powered to detect a difference
in use of EC.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
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Characteristics of excluded studies [ordered by study ID]
Blanchard 2003 Not a randomized controlled trial.
Ellertson 2001 Proportion of women in each treatment arm who became pregnant during follow-up not clearly reported; raw
data unavailable
Endres 2000 Not a randomized controlled trial.
Glasier 1998 Not a randomized controlled trial.
Glasier 2004 Not a randomized controlled trial.
Golden 2004 Randomized controlled trial of partner notification, not advance provision. Collected qualitative data on EC
interest.
Golden 2009 Intervention was advanced prescription, not advanced provision of emergency contraception
Harper 2005 Based on same data as Raine 2005, restricted to adolescents.
Larsson 2006 Not a randomized controlled trial.
London 2006 Review of Harper 2005.
Lovvorn 2000 Not a randomized controlled trial.
Ng 2003 Did not collect pregnancy data.
Petersen 2007 Did not collect pregnancy data.
Raine 2000 Not a randomized controlled trial.
Rocca 2007 Derivative of Raine 2005, did not assess pregnancy as an outcome
Sander 2009 Derivative of Raymond 2006, used only data from control arm.
Skibiak 1999 Not a randomized controlled trial.
Stehle 1999 Appears on PubMed as a randomized controlled trial, but actually a review of Glasier 1998
Teal 2008 Not a randomized controlled trial (alternate assignment).
Walker 2006 Intervention is not advance provision of emergency contraception
Walsh 2006 Not conducted as a randomized controlled trial since no attempt was made to follow-up 70% of randomized
participants.
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D A T A A N D A N A L Y S E S
Comparison 1. Advance provision vs. standard provision of emergency contraception




participants Statistical method Effect size
1 Pregnancy (at twelve-month
follow-up)
5 4728 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.76, 1.25]
2 Pregnancy (at seven-month
follow-up)
1 265 Odds Ratio (M-H, Fixed, 95% CI) 0.48 [0.18, 1.29]
3 Pregnancy (at six-month
follow-up)
8 6329 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.70, 1.20]
4 Pregnancy (at three-month
follow-up)
1 198 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.09, 2.74]
5 Pregnancy for levonorgestrel
regimens only
7 4271 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.64, 1.05]
6 Pregnancy for Yuzpe regimens
only
2 513 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.47, 1.74]
7 Pregnancy for mifepristone
regimens only
1 1948 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [0.74, 1.93]
8 Pregnancy for levonorgestrel or
Yuzpe regimens
10 5038 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.67, 1.03]
9 Sexually transmitted infections 4 3123 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.75, 1.37]
10 Ever use of emergency
contraceptives during trial
10 6971 Odds Ratio (M-H, Random, 95% CI) 2.47 [1.80, 3.40]
11 Multiple uses of emergency
contraceptives during trial
3 4574 Odds Ratio (M-H, Random, 95% CI) 4.13 [1.77, 9.63]
12 Mean time interval between
unprotected intercourse and
use of emergency contraception
2 1315 Mean Difference (IV, Random, 95% CI) -12.98 [-16.66, -
9.31]
13 Ever unprotected intercourse in
past two weeks
1 1140 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.66, 1.06]
14 Ever unprotected intercourse in
past month
1 254 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.46, 1.94]
15 Ever unprotected intercourse in
past three months
1 198 Odds Ratio (M-H, Fixed, 95% CI) 1.28 [0.73, 2.24]
16 Ever unprotected intercourse in
past six months
5 2024 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.79, 1.16]
17 Condom use at 12 months 3 3766 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.87, 1.16]
18 Condom use at 6 months 2 1247 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.66, 1.34]
19 Condom use at 3 months 1 296 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.48, 1.25]
20 Condom use in last month 1 254 Odds Ratio (M-H, Fixed, 95% CI) 1.54 [0.94, 2.53]
21 Condom use at last sex 1 265 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [0.71, 1.94]
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Analysis 1.1. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 1 Pregnancy (at twelve-month follow-up).
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 1 Pregnancy (at twelve-month follow-up)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hu 2005 38/974 32/974 24.9 % 1.20 [ 0.74, 1.93 ]
Jackson 2003 16/152 17/163 11.9 % 1.01 [ 0.49, 2.08 ]
Lo 2004 7/499 9/487 7.3 % 0.76 [ 0.28, 2.05 ]
Raymond 2006 67/724 70/717 51.6 % 0.94 [ 0.66, 1.34 ]
Schreiber 2009 3/16 8/22 4.4 % 0.40 [ 0.09, 1.86 ]
Total (95% CI) 2365 2363 100.0 % 0.98 [ 0.76, 1.25 ]
Total events: 131 (Treatment), 136 (Control)
Heterogeneity: Chi2 = 2.27, df = 4 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.2. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 2 Pregnancy (at seven-month follow-up).
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 2 Pregnancy (at seven-month follow-up)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schwartz 2008 6/127 13/138 100.0 % 0.48 [ 0.18, 1.29 ]
Total (95% CI) 127 138 100.0 % 0.48 [ 0.18, 1.29 ]
Total events: 6 (Treatment), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 1.3. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 3 Pregnancy (at six-month follow-up).
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 3 Pregnancy (at six-month follow-up)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belzer 2005 4/57 10/54 8.5 % 0.33 [ 0.10, 1.13 ]
Ekstrand 2008 4/158 3/136 2.8 % 1.15 [ 0.25, 5.24 ]
Gold 2004 13/119 18/135 13.4 % 0.80 [ 0.37, 1.71 ]
Hu 2005 10/904 5/911 4.4 % 2.03 [ 0.69, 5.95 ]
Jackson 2003 4/138 5/149 4.2 % 0.86 [ 0.23, 3.27 ]
Lo 2004 2/507 4/503 3.6 % 0.49 [ 0.09, 2.71 ]
Raine 2005 66/826 27/310 32.2 % 0.91 [ 0.57, 1.45 ]
Raymond 2006 37/708 37/714 31.1 % 1.01 [ 0.63, 1.61 ]
Total (95% CI) 3417 2912 100.0 % 0.92 [ 0.70, 1.20 ]
Total events: 140 (Treatment), 109 (Control)
Heterogeneity: Chi2 = 5.61, df = 7 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.4. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 4 Pregnancy (at three-month follow-up).
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 4 Pregnancy (at three-month follow-up)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hazari 2000 2/99 4/99 100.0 % 0.49 [ 0.09, 2.74 ]
Total (95% CI) 99 99 100.0 % 0.49 [ 0.09, 2.74 ]
Total events: 2 (Treatment), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.5. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 5 Pregnancy for levonorgestrel regimens only.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 5 Pregnancy for levonorgestrel regimens only
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belzer 2005 4/57 10/54 6.9 % 0.33 [ 0.10, 1.13 ]
Ekstrand 2008 4/158 3/136 2.3 % 1.15 [ 0.25, 5.24 ]
Lo 2004 7/499 9/487 6.5 % 0.76 [ 0.28, 2.05 ]
Raine 2005 66/826 27/310 26.0 % 0.91 [ 0.57, 1.45 ]
Raymond 2006 67/724 70/717 45.9 % 0.94 [ 0.66, 1.34 ]
Schreiber 2009 3/16 8/22 3.9 % 0.40 [ 0.09, 1.86 ]
Schwartz 2008 6/127 13/138 8.5 % 0.48 [ 0.18, 1.29 ]
Total (95% CI) 2407 1864 100.0 % 0.82 [ 0.64, 1.05 ]
Total events: 157 (Treatment), 140 (Control)
Heterogeneity: Chi2 = 5.05, df = 6 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.6. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 6 Pregnancy for Yuzpe regimens only.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 6 Pregnancy for Yuzpe regimens only
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hazari 2000 2/99 4/99 21.1 % 0.49 [ 0.09, 2.74 ]
Jackson 2003 16/152 17/163 78.9 % 1.01 [ 0.49, 2.08 ]
Total (95% CI) 251 262 100.0 % 0.90 [ 0.47, 1.74 ]
Total events: 18 (Treatment), 21 (Control)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.7. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 7 Pregnancy for mifepristone regimens only.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 7 Pregnancy for mifepristone regimens only
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hu 2005 38/974 32/974 100.0 % 1.20 [ 0.74, 1.93 ]
Total (95% CI) 974 974 100.0 % 1.20 [ 0.74, 1.93 ]
Total events: 38 (Treatment), 32 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.8. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 8 Pregnancy for levonorgestrel or Yuzpe regimens.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 8 Pregnancy for levonorgestrel or Yuzpe regimens
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belzer 2005 4/57 10/54 5.5 % 0.33 [ 0.10, 1.13 ]
Ekstrand 2008 4/158 3/136 1.8 % 1.15 [ 0.25, 5.24 ]
Gold 2004 13/119 18/135 8.7 % 0.80 [ 0.37, 1.71 ]
Hazari 2000 2/99 4/99 2.3 % 0.49 [ 0.09, 2.74 ]
Jackson 2003 16/152 17/163 8.5 % 1.01 [ 0.49, 2.08 ]
Lo 2004 7/499 9/487 5.2 % 0.76 [ 0.28, 2.05 ]
Raine 2005 66/826 27/310 20.9 % 0.91 [ 0.57, 1.45 ]
Raymond 2006 67/724 70/717 37.0 % 0.94 [ 0.66, 1.34 ]
Schreiber 2009 3/16 8/22 3.2 % 0.40 [ 0.09, 1.86 ]
Schwartz 2008 6/127 13/138 6.9 % 0.48 [ 0.18, 1.29 ]
Total (95% CI) 2777 2261 100.0 % 0.83 [ 0.67, 1.03 ]
Total events: 188 (Treatment), 179 (Control)
Heterogeneity: Chi2 = 5.70, df = 9 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.9. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 9 Sexually transmitted infections.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 9 Sexually transmitted infections
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ekstrand 2008 5/158 2/136 2.4 % 2.19 [ 0.42, 11.47 ]
Gold 2004 12/119 12/135 11.9 % 1.15 [ 0.50, 2.67 ]
Raine 2005 49/826 17/310 27.3 % 1.09 [ 0.62, 1.92 ]
Raymond 2006 49/725 53/714 58.4 % 0.90 [ 0.60, 1.35 ]
Total (95% CI) 1828 1295 100.0 % 1.01 [ 0.75, 1.37 ]
Total events: 115 (Treatment), 84 (Control)
Heterogeneity: Chi2 = 1.28, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.10. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 10 Ever use of emergency contraceptives during trial.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 10 Ever use of emergency contraceptives during trial
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Ekstrand 2008 54/172 29/157 10.5 % 2.02 [ 1.21, 3.38 ]
Gold 2004 26/119 20/135 9.1 % 1.61 [ 0.84, 3.06 ]
Hazari 2000 32/99 29/99 9.6 % 1.15 [ 0.63, 2.11 ]
Hu 2005 183/974 90/974 13.1 % 2.27 [ 1.73, 2.98 ]
Jackson 2003 28/152 9/163 7.7 % 3.86 [ 1.76, 8.49 ]
Lo 2004 149/499 63/487 12.6 % 2.87 [ 2.07, 3.97 ]
Raine 2005 309/826 65/310 12.8 % 2.25 [ 1.66, 3.06 ]
Raymond 2006 527/746 236/744 13.6 % 5.18 [ 4.15, 6.46 ]
Schreiber 2009 12/23 8/27 5.0 % 2.59 [ 0.81, 8.29 ]
Schwartz 2008 13/127 6/138 6.0 % 2.51 [ 0.92, 6.81 ]
Total (95% CI) 3737 3234 100.0 % 2.47 [ 1.80, 3.40 ]
Total events: 1333 (Treatment), 555 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 46.97, df = 9 (P<0.00001); I2 =81%
Test for overall effect: Z = 5.55 (P < 0.00001)
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Analysis 1.11. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 11 Multiple uses of emergency contraceptives during trial.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 11 Multiple uses of emergency contraceptives during trial
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Hu 2005 54/974 21/974 32.3 % 2.66 [ 1.60, 4.45 ]
Raine 2005 125/826 18/310 32.3 % 2.89 [ 1.73, 4.83 ]
Raymond 2006 381/746 81/744 35.3 % 8.54 [ 6.51, 11.21 ]
Total (95% CI) 2546 2028 100.0 % 4.13 [ 1.77, 9.63 ]
Total events: 560 (Treatment), 120 (Control)
Heterogeneity: Tau2 = 0.51; Chi2 = 23.76, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 3.28 (P = 0.0010)
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Analysis 1.12. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 12 Mean time interval between unprotected intercourse and use of emergency contraception.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 12 Mean time interval between unprotected intercourse and use of emergency contraception
Study or subgroup Treatment Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ekstrand 2008 172 15.57 (12.69) 157 26.38 (19.34) 42.7 % -10.81 [ -14.38, -7.24 ]
Lo 2004 499 13.9 (14.4) 487 28.5 (19.8) 57.3 % -14.60 [ -16.77, -12.43 ]
Total (95% CI) 671 644 100.0 % -12.98 [ -16.66, -9.31 ]
Heterogeneity: Tau2 = 4.91; Chi2 = 3.16, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 6.92 (P < 0.00001)
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Analysis 1.13. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 13 Ever unprotected intercourse in past two weeks.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 13 Ever unprotected intercourse in past two weeks
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Raymond 2006 323/568 350/572 100.0 % 0.84 [ 0.66, 1.06 ]
Total (95% CI) 568 572 100.0 % 0.84 [ 0.66, 1.06 ]
Total events: 323 (Treatment), 350 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
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Analysis 1.14. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 14 Ever unprotected intercourse in past month.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 14 Ever unprotected intercourse in past month
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gold 2004 16/119 19/135 100.0 % 0.95 [ 0.46, 1.94 ]
Total (95% CI) 119 135 100.0 % 0.95 [ 0.46, 1.94 ]
Total events: 16 (Treatment), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
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Analysis 1.15. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 15 Ever unprotected intercourse in past three months.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 15 Ever unprotected intercourse in past three months
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hazari 2000 47/99 41/99 100.0 % 1.28 [ 0.73, 2.24 ]
Total (95% CI) 99 99 100.0 % 1.28 [ 0.73, 2.24 ]
Total events: 47 (Treatment), 41 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
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Analysis 1.16. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 16 Ever unprotected intercourse in past six months.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 16 Ever unprotected intercourse in past six months
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belzer 2005 26/57 26/54 6.6 % 0.90 [ 0.43, 1.90 ]
Ekstrand 2008 54/121 45/107 12.0 % 1.11 [ 0.66, 1.88 ]
Jackson 2003 47/136 52/149 14.8 % 0.99 [ 0.60, 1.61 ]
Raine 2005 328/825 127/310 50.5 % 0.95 [ 0.73, 1.24 ]
Schwartz 2008 60/127 70/138 16.1 % 0.87 [ 0.54, 1.41 ]
Total (95% CI) 1266 758 100.0 % 0.96 [ 0.79, 1.16 ]
Total events: 515 (Treatment), 320 (Control)
Heterogeneity: Chi2 = 0.50, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
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Analysis 1.17. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 17 Condom use at 12 months.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 17 Condom use at 12 months
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hu 2005 625/822 629/817 41.0 % 0.95 [ 0.75, 1.19 ]
Lo 2004 395/499 391/487 22.4 % 0.93 [ 0.68, 1.27 ]
Raymond 2006 285/569 271/572 36.6 % 1.11 [ 0.88, 1.41 ]
Total (95% CI) 1890 1876 100.0 % 1.01 [ 0.87, 1.16 ]
Total events: 1305 (Treatment), 1291 (Control)
Heterogeneity: Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
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Analysis 1.18. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 18 Condom use at 6 months.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 18 Condom use at 6 months
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belzer 2005 21/57 21/54 21.4 % 0.92 [ 0.43, 1.97 ]
Raine 2005 99/826 39/310 78.6 % 0.95 [ 0.64, 1.41 ]
Total (95% CI) 883 364 100.0 % 0.94 [ 0.66, 1.34 ]
Total events: 120 (Treatment), 60 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
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Analysis 1.19. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 19 Condom use at 3 months.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 19 Condom use at 3 months
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ekstrand 2008 48/149 56/147 100.0 % 0.77 [ 0.48, 1.25 ]
Total (95% CI) 149 147 100.0 % 0.77 [ 0.48, 1.25 ]
Total events: 48 (Treatment), 56 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
0.01 0.1 1 10 100
Favours control Favours treatment
Analysis 1.20. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 20 Condom use in last month.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 20 Condom use in last month
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gold 2004 70/119 65/135 100.0 % 1.54 [ 0.94, 2.53 ]
Total (95% CI) 119 135 100.0 % 1.54 [ 0.94, 2.53 ]
Total events: 70 (Treatment), 65 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
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Analysis 1.21. Comparison 1 Advance provision vs. standard provision of emergency contraception,
Outcome 21 Condom use at last sex.
Review: Advance provision of emergency contraception for pregnancy prevention
Comparison: 1 Advance provision vs. standard provision of emergency contraception
Outcome: 21 Condom use at last sex
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schwartz 2008 49/127 48/138 100.0 % 1.18 [ 0.71, 1.94 ]
Total (95% CI) 127 138 100.0 % 1.18 [ 0.71, 1.94 ]
Total events: 49 (Treatment), 48 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
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WH A T ’ S N E W
Last assessed as up-to-date: 9 November 2009.
11 January 2010 New search has been performed Added information from 3 new included studies and noted new excluded
studies.
H I S T O R Y
Protocol first published: Issue 4, 2005
Review first published: Issue 2, 2007
14 April 2009 Amended Converted to new review format.
14 January 2007 New citation required and conclusions have changed Substantive amendment
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